Viewing Study NCT07170293

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:06 AM
Ignite Modification Date: 2026-01-03 @ 11:24 AM
Study NCT ID: NCT07170293
Status: RECRUITING
Last Update Posted: 2025-09-12
First Post: 2025-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Sponsor: Tianjin Medical University Second Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Solid Cancers View
Keywords:

Keywords

Keyword Brief Keyword Text View
None NRAS View
None Tunlametinib View
None MEK View